These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 30059145)

  • 1. Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.
    Guo Y; Chu X; Parrott NJ; Brouwer KLR; Hsu V; Nagar S; Matsson P; Sharma P; Snoeys J; Sugiyama Y; Tatosian D; Unadkat JD; Huang SM; Galetin A;
    Clin Pharmacol Ther; 2018 Nov; 104(5):865-889. PubMed ID: 30059145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
    El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
    Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
    Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
    Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
    Taskar KS; Pilla Reddy V; Burt H; Posada MM; Varma M; Zheng M; Ullah M; Emami Riedmaier A; Umehara KI; Snoeys J; Nakakariya M; Chu X; Beneton M; Chen Y; Huth F; Narayanan R; Mukherjee D; Dixit V; Sugiyama Y; Neuhoff S
    Clin Pharmacol Ther; 2020 May; 107(5):1082-1115. PubMed ID: 31628859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States.
    Sharma S; Suresh Ahire D; Prasad B
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S17-S35. PubMed ID: 33205430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.
    Pan Y; Hsu V; Grimstein M; Zhang L; Arya V; Sinha V; Grillo JA; Zhao P
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S122-31. PubMed ID: 27385170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.
    Zamek-Gliszczynski MJ; Lee CA; Poirier A; Bentz J; Chu X; Ellens H; Ishikawa T; Jamei M; Kalvass JC; Nagar S; Pang KS; Korzekwa K; Swaan PW; Taub ME; Zhao P; Galetin A;
    Clin Pharmacol Ther; 2013 Jul; 94(1):64-79. PubMed ID: 23588311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
    Li R; Barton HA; Varma MV
    Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters.
    Cheung KWK; van Groen BD; Burckart GJ; Zhang L; de Wildt SN; Huang SM
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1(Suppl 1):S56-S69. PubMed ID: 31502692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future.
    Rowland Yeo K; Gil Berglund E; Chen Y
    Clin Pharmacol Ther; 2024 Sep; 116(3):563-576. PubMed ID: 38686708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic and Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips.
    Prantil-Baun R; Novak R; Das D; Somayaji MR; Przekwas A; Ingber DE
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():37-64. PubMed ID: 29309256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance.
    Liang X; Lai Y
    Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):869-886. PubMed ID: 33793347
    [No Abstract]   [Full Text] [Related]  

  • 16. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.
    Jones HM; Mayawala K; Poulin P
    AAPS J; 2013 Apr; 15(2):377-87. PubMed ID: 23269526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions.
    Taskar KS; Harada I; Alluri RV
    Curr Drug Metab; 2021; 22(7):523-531. PubMed ID: 33397250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.
    Ellison CA
    Regul Toxicol Pharmacol; 2018 Nov; 99():61-77. PubMed ID: 30201539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.